Altreno (tretinoin) / Bausch Health - LARVOL DELTA

Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) - P4 | N=25 | Completed | Sponsor: Beth Israel Deaconess Medical Center | N=37 ➔ 25

Enrollment change • Acne Vulgaris

Drugs for acne. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Acne Vulgaris

Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) - P4 | N=37 | Completed | Sponsor: Beth Israel Deaconess Medical Center | Active, not recruiting ➔ Completed | N=60 ➔ 37 | Trial completion date: Mar 2023 ➔ Aug 2022 | Trial primary completion date: Feb 2023 ➔ Aug 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Acne Vulgaris

Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) - P4 | N=60 | Active, not recruiting | Sponsor: Beth Israel Deaconess Medical Center | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Mar 2023 | Trial primary completion date: Aug 2022 ➔ Feb 2023

Enrollment closed • Trial completion date • Trial primary completion date • Acne Vulgaris

Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream. (PubMed, J Drugs Dermatol) - "After 2 weeks of once-daily use, tretinoin 0.05% lotion was associated with less irritation and superior skin appearance/ sensation versus generic 0.05% cream, with most participants preferring the lotion over cream. These results demonstrate the importance of a well-designed vehicle formulation on tolerability and patient preference. J Drugs Dermatol. 2022;21(8): 875-880. doi:10.36849/JDD.6945."

Journal • Acne Vulgaris • Dermatology

Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Acne Vulgaris

Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients. (PubMed, J Dermatolog Treat) - P3 | "Post hoc analyses of changes in inflammatory/noninflammatory lesions and treatment success were conducted using phase 3 data: clindamycin phosphate/benzoyl peroxide (CP/BPO) 1.2%/3.75% gel (NCT01701024); tretinoin 0.05% lotion (NCT02965456 and NCT02932306; pooled); and tazarotene 0.045% lotion (NCT03168321 and NCT03168334; pooled). CP/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, and tazarotene 0.045% lotion were all effective in reducing acne lesions by ≥45% in overweight/obese patients with moderate-to-severe acne, comparable to the underweight-to-normal group. Efficacy of these topical acne treatments is not greatly impacted by BMI and may be affected more by the formulation."

Journal • Retrospective data • Acne Vulgaris • Obesity

A Prospective, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy, Safety, and Patient Satisfaction of Tretinoin 0.05% Lotion for Chest Rejuvenation. (PubMed, J Drugs Dermatol) - "Tretinoin 0.05% lotion delivered in a proprietary blend of hydrating ingredients offers a safe and efficacious option that has minimal downtime for patients seeking non-procedural photo-rejuvenation of the chest. The proprietary vehicle, containing hyaluronic acid, glycerin, and collagen, was crucial in minimizing irritation and producing at least a one-point improvement according to the 9 point photodamage scale and 30-40% improvement in photodamage as noted by the blinded evaluator percent improvement score in both the vehicle and active groups. J Drugs Dermatol. 2022;21(6):645-652. doi:10.36849/JDD.6658."

Clinical • Journal • Aesthetic Medicine • Dermatology

Clascoterone cream (Winlevi) for acne. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Acne Vulgaris

Single-Center, Prospective, Double-Blind, Evaluator-Blind, non-Randomized, Vehicle-Controlled Trial With a 1927 Nm Non-Ablative Fractionated Laser and Topical 0.05% Tretinoin Lotion for Facial Dyspigmentation and Photodamage. (PubMed, J Drugs Dermatol) - "In our study, patients tolerated the combination of 1927 nm thulium fiber laser and 0.05% tretinoin lotion well. Both groups resulted in significant reduction of hyperpigmentation and photodamage. Subject satisfaction and perceived improvement were temporarily lower at 30 days only when, combining 0.05% tretinoin lotion with 1927 nm thulium fiber laser. Future studies are needed to investigate the impact on efficacy when combining laser procedures with a longer duration of use or a higher concentration of topical tretinoin. J Drugs Dermatol. 2021;20(11):1174-1179. doi:10.36849/JDD.6182."

Clinical • Journal • Aesthetic Medicine

Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) - P4; N=60; Recruiting; Sponsor: Beth Israel Deaconess Medical Center; Trial primary completion date: Aug 2021 ➔ Aug 2022

Clinical • Trial primary completion date • Acne Vulgaris

[VIRTUAL] Impact of Body Mass Index (BMI) on Efficacy of Three Topical Acne Treatments in Patients with Moderate-to-Severe Acne (AAD-VMX 2021) - "This post hoc analysis investigated BMI impact on efficacy of clindamycin/benzoyl peroxide 1.2%/3.75% gel (C/BPO),[3] tretinoin 0.05% lotion (polymeric emulsion),[4,5] and tazarotene 0.045% lotion (polymeric emulsion)[6,7] using data from 5 phase 3, double-blind studies. For vehicle-treated participants, formulation type may have affected responses; greater lesion reductions were observed with polymeric-emulsion lotion vehicles versus gel vehicle and improvements with both polymeric-emulsion vehicles were greatest in obese participants. In summary, BMI did not affect treatment outcomes with 3 topical acne medications (C/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, tazarotene 0.045% lotion); results are notable given the limited clinical data on BMI and potential impacts on the efficacy of acne treatments."

Clinical • Acne Vulgaris • Obesity

Altreno for Chest Rejuvenation (clinicaltrials.gov) - P4; N=40; Active, not recruiting; Sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Recruiting ➔ Active, not recruiting

Enrollment closed

Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) - P4; N=60; Recruiting; Sponsor: Beth Israel Deaconess Medical Center; Not yet recruiting ➔ Recruiting; Initiation date: Oct 2020 ➔ Mar 2021; Trial primary completion date: May 2021 ➔ Aug 2021

Clinical • Enrollment open • Trial initiation date • Trial primary completion date • Acne Vulgaris

Drugs for acne. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Acne Vulgaris • Infectious Disease • Novel Coronavirus Disease

A Split-face, Controlled Study to Assess the Compatibility of Tretinoin 0.05% Acne Lotion with Facial Foundation Makeup. (PubMed, J Clin Aesthet Dermatol) - "Participants reported overall satisfaction with the tretinoin lotion-treated side. Tretinoin 0.05% lotion did not interfere with facial makeup application or wearability and was well tolerated."

Clinical • Journal • Acne Vulgaris

Altreno for Chest Rejuvenation (clinicaltrials.gov) - P4; N=40; Recruiting; Sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Enrollment open • Trial completion date • Trial primary completion date

Drug-Induced Hearing Loss in Children: An Analysis of Spontaneous Reports in the French PharmacoVigilance Database. (PubMed, Paediatr Drugs) - "This study shows that about three out of four cases of drug-induced hearing loss in the pediatric population were "serious". It also underlines the under-reporting of these ADRs and the importance of strengthening hearing monitoring in children during and long after drug exposure."

Journal • Otorhinolaryngology • Pediatrics

Actinomycetoma presenting as focal neurologic deficits in immunocompetent man due to recently identified Nocardia Vulneris (AAD 2019) - "...Previous treatment included a brief course of doxycycline and an incomplete course of oral isotretinoin without improvement...Empiric treatment consisted of ceftriaxone, daptomycin, and metronidazole...Actinomycetoma is significantly more prevalent in tropical and subtropical environments; however, the recently described N vulneris is noted in more temperate climates. N vulneris has demonstrated susceptibility to sulfonamide and aminoglycoside based regimens."